Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45


OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.

J Urol. 2017 Feb;197(2S):S216-S223. doi: 10.1016/j.juro.2016.10.109. Epub 2016 Dec 22.


Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence.

Wallis CJ, Lundeen C, Golda N, Brotherhood H, Pommerville P, Carr L.

Can Urol Assoc J. 2016 Aug;10(7-8):277-280.


Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.

Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL.

J Urol. 2016 Oct;196(4):1082-9. doi: 10.1016/j.juro.2016.04.069. Epub 2016 Apr 27.


Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.

Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, De Ridder D, Jenkins B, Magyar A, Chapple C; 191622-096 Investigators.

J Urol. 2016 Sep;196(3):791-800. doi: 10.1016/j.juro.2016.03.146. Epub 2016 Mar 30.


Effect of surgical approach on erectile function recovery following bilateral nerve-sparing radical prostatectomy: an evaluation utilising data from a randomised, double-blind, double-dummy multicentre trial of tadalafil vs placebo.

Stolzenburg JU, Graefen M, Kriegel C, Michl U, Martin Morales A, Pommerville PJ, Manning M, Büttner H, Henneges C, Schostak M.

BJU Int. 2015 Aug;116(2):241-51. doi: 10.1111/bju.13030. Epub 2015 Apr 20.


A surgical challenge: Idiopathic scrotal elephantiasis.

Brotherhood HL, Metcalfe M, Goldenberg L, Pommerville P, Bowman C, Naysmith D.

Can Urol Assoc J. 2014 Jul;8(7-8):E500-7. doi: 10.5489/cuaj.1739.


OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.

J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14.


Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.

Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR.

J Urol. 2013 Apr;189(4):1421-6. doi: 10.1016/j.juro.2012.11.003. Epub 2012 Nov 7.


Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.

Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P.

Neurourol Urodyn. 2013 Mar;32(3):242-9. doi: 10.1002/nau.22293. Epub 2012 Sep 10.


Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.

Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, Viktrup L.

BJU Int. 2011 Apr;107(7):1110-6. doi: 10.1111/j.1464-410X.2010.09687.x. Epub 2011 Jan 18.


Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study.

Herschorn S, Pommerville P, Stothers L, Egerdie B, Gajewski J, Carlson K, Radomski S, Drutz H, Schulz J, Barkin J, Hirshberg E, Corcos J.

Curr Med Res Opin. 2011 Feb;27(2):375-82. doi: 10.1185/03007995.2010.541433. Epub 2010 Dec 23.


Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P.

Eur Urol. 2011 May;59(5):747-54. doi: 10.1016/j.eururo.2010.11.024. Epub 2010 Nov 24.


Treatment of moderate to severe female stress urinary incontinence with the adjustable continence therapy (ACT) device after failed surgical repair.

Aboseif SR, Sassani P, Franke EI, Nash SD, Slutsky JN, Baum NH, Le Tu M, Galloway NT, Pommerville PJ, Sutherland SE.

World J Urol. 2011 Apr;29(2):249-53. doi: 10.1007/s00345-010-0589-4. Epub 2010 Oct 20.


Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.


GnRH antagonists in the treatment of advanced prostate cancer.

Pommerville PJ, de Boer JG.

Can J Urol. 2010 Apr;17(2):5063-70. Review.


Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.


Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F.

J Urol. 2010 May;183(5):1892-8. doi: 10.1016/j.juro.2010.01.012. Epub 2010 Mar 29.


Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group.

N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.

Supplemental Content

Loading ...
Support Center